Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed No phase listed Observational

Nova Max Creatinine and eGFR Meter System

ClinicalTrials.gov ID: NCT05118074

Public ClinicalTrials.gov record NCT05118074. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 10:37 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Nova Max Creatinine and eGFR Meter System - Evaluation

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

To assess the performance of the Nova Max Creatinine and eGFR assay in the hands of CLIA-Waived Point-of-Care users in at least three (3) distinct Point-of-Care clinical settings on venous, and capillary blood and compare the performance characteristics to a traceable laboratory reference method (the Siemens EXL creatinine determination). To assess the Ease of Use of the Nova Max Creatinine and eGFR Meter System in the hands of the intended CLIA-Waived Point-of-Care users.

Study identification

NCT ID
NCT05118074
Recruitment status
Completed
Study type
Observational
Phase
Not listed
Lead sponsor
Nova Biomedical
Industry
Enrollment
360 participants

Conditions and interventions

Interventions

Diagnostic Test

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jun 8, 2021 (Actual)
Primary completion
Apr 15, 2024 (Actual)
Completion
Apr 15, 2024 (Actual)
Last update posted
Mar 13, 2025

2021 – 2024

United States locations

U.S. sites
3
U.S. states
1
U.S. cities
3
Facility City State ZIP Site status
South Florida Research Organization Medley Florida 33166 —
Excellence Medical Research Miami Gardens Florida 33169 —
Charisma Medical and Research Center Miami Lakes Florida 33014 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT05118074, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Mar 13, 2025 · Synced Nov 7, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT05118074 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →